Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mindeudesivir hydrobromide + cyclosporine
- Development stage
- Preclinical
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of **mindeudesivir hydrobromide** (also known as VV116 or JT001) and **cyclosporine**. Mindeudesivir hydrobromide is an *oral nucleoside analog antiviral* related to remdesivir, developed to inhibit replication of SARS-CoV-2 by targeting viral RNA-dependent RNA polymerase. Cyclosporine is an *immunosuppressant* that inhibits calcineurin, blocking T-cell activation and IL-2 production. Combination of mindeudesivir (a direct antiviral) and cyclosporine (with both immunosuppressive and potential antiviral effects) has shown **synergistic inhibition of coronavirus replication and inflammatory cytokine production (including IL-6)** in cellular models, supporting investigation for COVID-19 and cytokine storm mitigation[1][5].
- Other names
- mindeudesivir hydrobromide + cyclosporine
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)CN (Calcineurin)
Beyond the preview
Go deeper on mindeudesivir hydrobromide + cyclosporine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mindeudesivir hydrobromide + cyclosporine.